Role of mitochondrial homeostasis and dynamics in Alzheimer's disease

Neurobiology of Disease

Volumn 51, Issue , 2013, Pages 3-12

  Selfridge, J Eva ^a   Lezi, E ^b   Lu, Jianghua ^a   Swerdlow, Russell H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b University of Kansas School of the Health Professions   (United States)

Author keywords

Alzheimer's disease; Autophagy; Bioenergetics; Biogenesis; Fission; Mitochondria; Mitochondrial DNA; Mitochondrial dysfunction; Mitochondrial medicine

Indexed keywords

AMYLOID BETA PROTEIN; CYTOCHROME C OXIDASE; MITOCHONDRIAL DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; UBIDECARENONE;

ALZHEIMER DISEASE; AMYLOIDOSIS; AUTOPHAGY; BIOENERGY; BIOGENESIS; CELL TRANSPORT; CYTOCHROME C OXIDASE DEFICIENCY; DISEASE TRANSMISSION; ENDOPHENOTYPE; ENZYME ACTIVITY; EXERCISE INTENSITY; GENE EXPRESSION REGULATION; GENE MUTATION; GENOTYPE; HOMEOSTASIS; HUMAN; HYBRID CELL; MITOCHONDRIAL DYNAMICS; NEUROPATHOLOGY; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; ANIMALS; HOMEOSTASIS; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DYNAMICS;

EID: 84871417031     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.12.057     Document Type: Review

References (196)

1. Adlard P.A., et al. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J. Neurosci. 2005, 25:4217-4221.
2. Adler V., et al. Regulation of JNK signaling by GSTp. EMBO J. 1999, 18:1321-1334.
3. Adler V., et al. Role of redox potential and reactive oxygen species in stress signaling. Oncogene 1999, 18:6104-6111.
4. Alleyne T., et al. Unraveling the role of metal ions and low catalytic activity of cytochrome C oxidase in Alzheimer's disease. J. Mol. Neurosci. 2011, 43:284-289.
5. Alzheimer A., et al. Uber eine eigenartige Erkrankung der Hirnrinde. Allg. Z Psychiat. Psych-Gerichtl Med. 1907, 64:146-148.
6. Apostolova N., et al. Autophagy as a rescue mechanism in efavirenz-induced mitochondrial dysfunction: a lesson from hepatic cells. Autophagy 2011, 7:1402-1404.
7. Apostolova N., et al. Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy. Hepatology 2011, 54:1009-1019.
8. Berlau D.J., et al. APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology 2009, 72:829-834.
9. Berti V., et al. Structural brain changes in normal individuals with a maternal history of Alzheimer's. Neurobiol. Aging 2011, 32:2325.e17-2325.e26.
10. Bielarczyk H., et al. RS-alpha-lipoic acid protects cholinergic cells against sodium nitroprusside and amyloid-beta neurotoxicity through restoration of acetyl-CoA level. J. Neurochem. 2006, 98:1242-1251.
11. Blass J.P., et al. The role of the metabolic lesion in Alzheimer's disease. J. Alzheimers Dis. 2002, 4:225-232.
12. Boland B., et al. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J. Neurosci. 2008, 28:6926-6937.
13. Bosetti F., et al. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol. Aging 2002, 23:371-376.
14. Boumezbeur F., et al. The contribution of blood lactate to brain energy metabolism in humans measured by dynamic 13C nuclear magnetic resonance spectroscopy. J. Neurosci. 2010, 30:13983-13991.
15. Boveris A., Navarro A. Systemic and mitochondrial adaptive responses to moderate exercise in rodents. Free Radic. Biol. Med. 2008, 44:224-229.
16. Braidy N., et al. Age related changes in NAD+ metabolism oxidative stress and Sirt1 activity in wistar rats. PLoS One 2011, 6:e19194.
17. Brody D.L., et al. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science 2008, 321:1221-1224.
18. Calkins M.J., Reddy P.H. Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. Biochim. Biophys. Acta 2011, 1812:507-513.
19. Calkins M.J., et al. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum. Mol. Genet. 2011, 20:4515-4529.
20. Cardoso S.M., et al. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol. Aging 2004, 25:105-110.
21. Cardoso S.M., et al. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J. Neurochem. 2004, 89:1417-1426.
22. Carling D., et al. Mammalian AMP-activated protein kinase is homologous to yeast and plant protein kinases involved in the regulation of carbon metabolism. J. Biol. Chem. 1994, 269:11442-11448.
23. Caspersen C., et al. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J. 2005, 19:2040-2041.
24. Cataldo A.M., et al. Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron 1995, 14:671-680.
25. Chen H., et al. Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell 2007, 130:548-562.
26. Cho J.Y., et al. The combination of exercise training and alpha-lipoic acid treatment has therapeutic effects on the pathogenic phenotypes of Alzheimer's disease in NSE/APPsw-transgenic mice. Int. J. Mol. Med. 2010, 25:337-346.
27. Corder E.H., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
28. Corrada M.M., et al. Prevalence of dementia after age 90: results from the 90+ study. Neurology 2008, 71:337-343.
29. Corrada M.M., et al. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann. Neurol. 2010, 67:114-121.
30. Crespo J.L., et al. Inhibition of target of rapamycin signaling by rapamycin in the unicellular green alga Chlamydomonas reinhardtii. Plant Physiol. 2005, 139:1736-1749.
31. Crouch P.J., et al. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J. Neurosci. 2005, 25:672-679.
32. Cui L., et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
33. Cunningham J.T., et al. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature 2007, 450:736-740.
34. Cupples L.A., et al. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet. Med. 2004, 6:192-196.
35. Curti D., et al. Oxidative metabolism in cultured fibroblasts derived from sporadic Alzheimer's disease (AD) patients. Neurosci. Lett. 1997, 236:13-16.
36. Dai J., et al. Impaired axonal transport of cortical neurons in Alzheimer's disease is associated with neuropathological changes. Brain Res. 2002, 948:138-144.
37. Daitoku H., et al. Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR. Diabetes 2003, 52:642-649.
38. De Vos K.J., et al. Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum. Mol. Genet. 2007, 16:2720-2728.
39. Debette S., et al. Association of parental dementia with cognitive and brain MRI measures in middle-aged adults. Neurology 2009, 73:2071-2078.
40. Donmez G., et al. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 2010, 142:320-332.
41. Duara R., et al. A comparison of familial and sporadic Alzheimer's disease. Neurology 1993, 43:1377-1384.
42. Edland S.D., et al. Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance. Neurology 1996, 47:254-256.
43. Ehrenkrantz D., et al. Genetic epidemiological study of maternal and paternal transmission of Alzheimer's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 1999, 88:378-382.
44. Evans D.A., et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989, 262:2551-2556.
45. Farber S.A., et al. Acceleration of phosphatidylcholine synthesis and breakdown by inhibitors of mitochondrial function in neuronal cells: a model of the membrane defect of Alzheimer's disease. FASEB J. 2000, 14:2198-2206.
46. Farrer L.A., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278:1349-1356.
47. Filomeni G., et al. Reactive oxygen species-dependent c-Jun NH2-terminal kinase/c-Jun signaling cascade mediates neuroblastoma cell death induced by diallyl disulfide. Cancer Res. 2003, 63:5940-5949.
48. Filomeni G., et al. Disulfide relays and phosphorylative cascades: partners in redox-mediated signaling pathways. Cell Death Differ. 2005, 12:1555-1563.
49. Finck B.N., Kelly D.P. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J. Clin. Invest. 2006, 116:615-622.
50. Finck B.N., et al. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab. 2006, 4:199-210.
51. Finkel T. Signal transduction by reactive oxygen species. J. Cell Biol. 2011, 194:7-15.
52. Fukui H., et al. Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14163-14168.
53. Gabbita S.P., et al. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J. Neurochem. 1998, 71:2034-2040.
54. Gabuzda D., et al. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J. Biol. Chem. 1994, 269:13623-13628.
55. Gallagher C.N., et al. The human brain utilizes lactate via the tricarboxylic acid cycle: a 13C-labelled microdialysis and high-resolution nuclear magnetic resonance study. Brain 2009, 132:2839-2849.
56. Galvan V., et al. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7130-7135.
57. Garcia-Mesa Y., et al. Physical exercise protects against Alzheimer's disease in 3xTg-AD mice. J. Alzheimers Dis. 2011, 24:421-454.
58. Gasparini L., et al. Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Neurosci. Lett. 1997, 231:113-117.
59. Gibson G.E., et al. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch. Neurol. 1988, 45:836-840.
60. Gibson G.E., et al. Abnormalities of mitochondrial enzymes in Alzheimer disease. J. Neural Transm. 1998, 105:855-870.
61. Goate A., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349:704-706.
62. Good P.F., et al. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann. Neurol. 1992, 31:286-292.
63. Gotoh Y., Cooper J.A. Reactive oxygen species- and dimerization-induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-alpha signal transduction. J. Biol. Chem. 1998, 273:17477-17482.
64. Green R.C., et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 2002, 287:329-336.
65. Greer E.L., et al. AMP-activated protein kinase and FoxO transcription factors in dietary restriction-induced longevity. Ann. N. Y. Acad. Sci. 2009, 1170:688-692.
66. Guarente L. Franklin H. Epstein Lecture: sirtuins, aging, and medicine. N. Engl. J. Med. 2011, 364:2235-2244.
67. Guo X., et al. Epigenetic mechanisms of amyloid-beta production in anisomycin-treated SH-SY5Y cells. Neuroscience 2011, 194:272-281.
68. Gutzmann H., Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. J. Neural Transm. Suppl. 1998, 54:301-310.
69. Guyant-Marechal L., et al. Variations in the APP gene promoter region and risk of Alzheimer disease. Neurology 2007, 68:684-687.
70. Hager K., et al. Alpha-lipoic acid as a new treatment option for Alzheimer's disease-a 48months follow-up analysis. J. Neural Transm. Suppl. 2007, 189-193.
71. Hansson Petersen C.A., et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13145-13150.
72. Hardie D.G., Hawley S.A. AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays 2001, 23:1112-1119.
73. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 1991, 12:383-388.
74. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
75. Herrmann N., et al. Current and emerging drug treatment options for Alzheimer's disease: a systematic review. Drugs 2011, 71:2031-2065.
76. Hirai K., et al. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 2001, 21:3017-3023.
77. Hollenbeck P.J., Saxton W.M. The axonal transport of mitochondria. J. Cell Sci. 2005, 118:5411-5419.
78. Honea R.A., et al. Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology 2010, 74:113-120.
79. Honea R.A., et al. Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease. Neurology 2011, 76:822-829.
80. Huang X., et al. Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann. N. Y. Acad. Sci. 2004, 1012:153-163.
81. 2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:534-538.
82. Jack C.R., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
83. Jager S., et al. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12017-12022.
84. Kang J.E., et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009, 326:1005-1007.
85. Katzman R. Editorial: the prevalence and malignancy of Alzheimer disease. A major killer. Arch. Neurol. 1976, 33:217-218.
86. Khan S.M., et al. Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann. Neurol. 2000, 48:148-155.
87. Kish S.J., et al. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem. 1992, 59:776-779.
88. Klatzo I., et al. Experimental production of neurofibrillary degeneration. I. Light microscopic observations. J. Neuropathol. Exp. Neurol. 1965, 24:187-199.
89. Lagouge M., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
90. Lehman J.J., et al. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J. Clin. Invest. 2000, 106:847-856.
91. Levy-Lahad E., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995, 269:973-977.
92. Li Z., et al. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004, 119:873-887.
93. Lin J., et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002, 418:797-801.
94. Lombard D.B., et al. Mitochondrial sirtuins in the regulation of mitochondrial activity and metabolic adaptation. Handb. Exp. Pharmacol. 2011, 163-188.
95. Lustbader J.W., et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004, 304:448-452.
96. Ma T., et al. Amyloid beta-induced impairments in hippocampal synaptic plasticity are rescued by decreasing mitochondrial superoxide. J. Neurosci. 2011, 31:5589-5595.
97. MacAskill A.F., et al. Mitochondrial trafficking and the provision of energy and calcium buffering at excitatory synapses. Eur. J. Neurosci. 2010, 32:231-240.
98. Manczak M., et al. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 2006, 15:1437-1449.
99. Manczak M., et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J. Alzheimers Dis. 2010, 20(Suppl. 2):S609-S631.
100. Manczak M., et al. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum. Mol. Genet. 2011, 20:2495-2509.
101. Massaad C.A., et al. Mitochondrial superoxide contributes to blood flow and axonal transport deficits in the Tg2576 mouse model of Alzheimer's disease. PLoS One 2010, 5:e10561.
102. Mattson M.P., et al. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008, 60:748-766.
103. Mecocci P., et al. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 1994, 36:747-751.
104. Meley D., et al. AMP-activated protein kinase and the regulation of autophagic proteolysis. J. Biol. Chem. 2006, 281:34870-34879.
105. Mihaylova M.M., Shaw R.J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 2011, 13:1016-1023.
106. Molteni R., et al. Exercise reverses the harmful effects of consumption of a high-fat diet on synaptic and behavioral plasticity associated to the action of brain-derived neurotrophic factor. Neuroscience 2004, 123:429-440.
107. Moreira P.I., et al. Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J. Alzheimers Dis. 2007, 12:195-206.
108. Moreira P.I., et al. Autophagocytosis of mitochondria is prominent in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2007, 66:525-532.
109. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 2005, 32:486-510.
110. Mosconi L., et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19067-19072.
111. Mosconi L., et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 2009, 72:513-520.
112. Mosconi L., et al. Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's. Biol. Psychiatry 2010, 68:913-921.
113. Mosconi L., et al. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:5949-5954.
114. Mosconi L., et al. Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer's disease. J. Alzheimers Dis. 2011, 27:483-490.
115. Murphy M.P., Smith R.A. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv. Drug Deliv. Rev. 2000, 41:235-250.
116. Mutisya E.M., et al. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem. 1994, 63:2179-2184.
117. Nakae J., et al. Forkhead transcription factor FoxO1 in adipose tissue regulates energy storage and expenditure. Diabetes 2008, 57:563-576.
118. Nakae J., et al. The FoxO transcription factors and metabolic regulation. FEBS Lett. 2008, 582:54-67.
119. Nemoto S., et al. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J. Biol. Chem. 2005, 280:16456-16460.
120. Nixon R.A., Yang D.S. Autophagy failure in Alzheimer's disease-locating the primary defect. Neurobiol. Dis. 2011, 43:38-45.
121. Nixon R.A., et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 2005, 64:113-122.
122. Noda T., Ohsumi Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J. Biol. Chem. 1998, 273:3963-3966.
123. Nunomura A., et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 1999, 19:1959-1964.
124. Nunomura A., et al. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2001, 60:759-767.
125. Ogonovszky H., et al. The effects of moderate-, strenuous- and over-training on oxidative stress markers, DNA repair, and memory, in rat brain. Neurochem. Int. 2005, 46:635-640.
126. Onyango I.G., et al. Regulation of neuron mitochondrial biogenesis and relevance to brain health. Biochim. Biophys. Acta 2010, 1802:228-234.
127. Paccalin M., et al. Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2006, 22:320-326.
128. Parker W.D. Sporadic neurologic disease and the electron transport chain: a hypothesis. Proceedings of the 1989 Scientific Meeting of the American Society for Neurological Investigation: New Developments in Neuromuscular Disease 1990, Indiana University Printing Services, Bloomington, Indiana. R.M. Pascuzzi (Ed.).
129. Parker W.D., Parks J.K. Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization. Neurology 1995, 45:482-486.
130. Parker W.D., et al. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 1990, 40:1302-1303.
131. Parker W.D., et al. Electron transport chain defects in Alzheimer's disease brain. Neurology 1994, 44:1090-1096.
132. Payami H., Hoffbuhr K. Lack of evidence for maternal effect in familial Alzheimer's disease. Genet. Epidemiol. 1993, 10:461-464.
133. Peterson C., Goldman J.E. Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:2758-2762.
134. Pigino G., et al. Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J. Neurosci. 2003, 23:4499-4508.
135. Qin W., et al. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch. Neurol. 2009, 66:352-361.
136. Quinn J.F., et al. Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol. Aging 2007, 28:213-225.
137. Quistorff B., et al. Lactate fuels the human brain during exercise. FASEB J. 2008, 22:3443-3449.
138. Radak Z., et al. Regular exercise improves cognitive function and decreases oxidative damage in rat brain. Neurochem. Int. 2001, 38:17-23.
139. Rahman S., Islam R. Mammalian Sirt1: insights on its biological functions. Cell Commun. Signal. 2011, 9:9-11.
140. Reddy P.H., Shirendeb U.P. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Biochim. Biophys. Acta 2011, 1822:101-110.
141. Reddy P.H., et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum. Mol. Genet. 2004, 13:1225-1240.
142. Reznick R.M., Shulman G.I. The role of AMP-activated protein kinase in mitochondrial biogenesis. J. Physiol. 2006, 574:33-39.
143. Rhee J., et al. Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4012-4017.
144. Saitoh M., et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998, 17:2596-2606.
145. Santos R.X., et al. A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer's disease. J. Alzheimers Dis. 2010, 20(Suppl. 2):S401-S412.
146. Saraiva A.A., et al. Mitochondrial abnormalities in cortical dendrites from patients with Alzheimer's disease. J. Submicrosc. Cytol. 1985, 17:459-464.
147. Sayre L.M., et al. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 1997, 68:2092-2097.
148. Schuchmann S., et al. Monitoring NAD(P)H autofluorescence to assess mitochondrial metabolic functions in rat hippocampal-entorhinal cortex slices. Brain Res. Brain Res. Protoc. 2001, 7:267-276.
149. Scott R.C., et al. Role and regulation of starvation-induced autophagy in the Drosophila fat body. Dev. Cell 2004, 7:167-178.
150. Shen H.M., Liu Z.G. JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic. Biol. Med. 2006, 40:928-939.
151. Sheng B., et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J. Neurochem. 2012, 120:419-429.
152. Sherrington R., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995, 375:754-760.
153. Shigenaga M.K., et al. Oxidative damage and mitochondrial decay in aging. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:10771-10778.
154. Silverman J.M., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part VI. Family history assessment: a multicenter study of first-degree relatives of Alzheimer's disease probands and nondemented spouse controls. Neurology 1994, 44:1253-1259.
155. Silverman J.M., et al. Variability of familial risk of Alzheimer disease across the late life span. Arch. Gen. Psychiatry 2005, 62:565-573.
156. Smith C.D., et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:10540-10543.
157. Sorbi S., et al. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann. Neurol. 1983, 13:72-78.
158. Sperling R.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
159. Stefanatos R., Sanz A. Mitochondrial complex I: a central regulator of the aging process. Cell Cycle 2011, 10:1528-1532.
160. Sterky F.H., et al. Impaired mitochondrial transport and Parkin-independent degeneration of respiratory chain-deficient dopamine neurons in vivo. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12937-12942.
161. St-Pierre J., et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006, 127:397-408.
162. Su B., et al. Abnormal mitochondrial dynamics-a novel therapeutic target for Alzheimer's disease?. Mol. Neurobiol. 2010, 41:87-96.
163. Suzuki A., et al. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 2011, 144:810-823.
164. Swerdlow R.H. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J. Neurosci. Res. 2007, 85:3416-3428.
165. Swerdlow R.H. beta-Apptists and Tauists, it is time for a sermon from the book of biogenesis. J. Neurochem. 2012, 120:347-349.
166. Swerdlow, R.H., in press. Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxid. Redox Signal.
167. Swerdlow R.H., Khan S.M. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med. Hypotheses 2004, 63:8-20.
168. Swerdlow R.H., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis: an update. Exp. Neurol. 2009, 218:308-315.
169. Swerdlow R.H., Kish S.J. Mitochondria in Alzheimer's disease. Int. Rev. Neurobiol. 2002, 53:341-385.
170. Swerdlow R.H., et al. Cybrids in Alzheimer's disease: a cellular model of the disease?. Neurology 1997, 49:918-925.
171. Swerdlow R.H., et al. The Alzheimer's disease mitochondrial cascade hypothesis. J. Alzheimers Dis. 2010, 20(Suppl. 2):S265-S279.
172. Tamagno E., et al. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol. Dis. 2002, 10:279-288.
173. Tee A.R., et al. Analysis of mTOR signaling by the small G-proteins, Rheb and RhebL1. FEBS Lett. 2005, 579:4763-4768.
174. Thal L.J., et al. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology 2003, 61:1498-1502.
175. Thies W., Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimers Dement. 2011, 7:208-244.
176. Trimmer P.A., Borland M.K. Differentiated Alzheimer's disease transmitochondrial cybrid cell lines exhibit reduced organelle movement. Antioxid. Redox Signal. 2005, 7:1101-1109.
177. Twig G., et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J. 2008, 27:433-446.
178. Twig G., et al. Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view. Biochim. Biophys. Acta 2008, 1777:1092-1097.
179. Valla J., et al. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion 2006, 6:323-330.
180. van Hall G., et al. Blood lactate is an important energy source for the human brain. J. Cereb. Blood Flow Metab. 2009, 29:1121-1129.
181. Verhey F.R. Alois Alzheimer (1864-1915). J. Neurol. 2009, 256:502-503.
182. Wang X., et al. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. Am. J. Pathol. 2008, 173:470-482.
183. Wang X., et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19318-19323.
184. Wang X., et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J. Neurosci. 2009, 29:9090-9103.
185. Wareski P., et al. PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons. J. Biol. Chem. 2009, 284:21379-21385.
186. Webster M.T., et al. The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. J. Neural Transm. 1998, 105:839-853.
187. Weyer G., et al. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology 1997, 36:73-82.
188. Wolfe M.S., et al. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999, 398:513-517.
189. Wong-Riley M., et al. Cytochrome oxidase in Alzheimer's disease: biochemical, histochemical, and immunohistochemical analyses of the visual and other systems. Vision Res. 1997, 37:3593-3608.
190. Wyss M.T., et al. In vivo evidence for lactate as a neuronal energy source. J. Neurosci. 2011, 31:7477-7485.
191. Yang Z., Klionsky D.J. Eaten alive: a history of macroautophagy. Nat. Cell Biol. 2011, 12:814-822.
192. Yang X., et al. Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. J. Mol. Neurosci. 2008, 34:165-171.
193. Yang X., et al. Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease. J. Mol. Neurosci. 2010, 41:110-113.
194. Youle R.J., Narendra D.P. Mechanisms of mitophagy. Nat. Rev. Mol. Cell Biol. 2011, 12:9-14.
195. Yu L., Yang S.J. AMP-activated protein kinase mediates activity-dependent regulation of peroxisome proliferator-activated receptor gamma coactivator-1alpha and nuclear respiratory factor 1 expression in rat visual cortical neurons. Neuroscience 2010, 169:23-38.
196. Zhang F., et al. Protective effects and mechanisms of sirtuins in the nervous system. Prog. Neurobiol. 2011, 95:373-395.